NCT00557596 - A Phase 1-2, XIAP Antisense AEG35156 With Gemcitabine in Patients With Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

CarcinomaPancreas

Interventions

DRUG

AEG35156

AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1

Trial Locations (4)

44718

Gabrail Cancer Center, Canton

85258

Scottsdale Healthcare - SHEA, Scottsdale

85259

Mayo Clinic Arizona, Scottsdale

85724

Arizona Cancer Center - University of Arizona, Tucson